fbpx

Exerpts from the publication

Background
Ayahuasca is a psychoactive Amazonian brew which has emerging data indicating that it has antidepressant and anxiolytic properties.

Methods
This paper uses data from the Global Ayahuasca Project (GAP), which was undertaken across 2017–2020 and involved 11912 people, to examine the perceived effects of Ayahuasca consumption on affective symptoms. The study focused on the subsample reporting depression or anxiety diagnoses at time of Ayahuasca consumption.

Results
Of participants reporting depression (n = 1571) or anxiety (n = 1125) at the time of consuming Ayahuasca, 78% reported that their depression was either ‘very much’ improved (46%), or ‘completely resolved’ (32%); while 70% of those with anxiety reported that their symptoms were ‘very much’ improved (54%), or ‘completely resolved’ (16%). A range of factors were associated with greater reported affective symptoms improvement, including subjective mystical experience, number of Ayahuasca sessions, and number of personal psychological insights experienced. 2.7% and 4.5% of drinkers with depression or anxiety, respectively, reported worsening of symptoms. (Limitations: This study is recognized as a cross-sectional analysis which cannot assess treatment efficacy. Selection bias may exist due to survey-respondents with favorable experience being potentially biased towards participation)

Conclusions
Drinkers of Ayahuasca in naturalistic settings perceived remarkable benefits for their affective symptoms in this survey assessment. There is no obvious evidence of negative mental health effects being associated with long-term consumption. Additional randomized controlled trial evidence is required to establish the efficacy of Ayahuasca in affective disorders, and to understand the worsened symptoms reported by a small percentage of drinkers.

Read more

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder

Davis, A,K., Barrett, F.S., Darrick G. May, D.G., Cosimano, M.P., Sepeda, N.D., Johnson, M.W., Finan, P.H., & Griffiths, R.R.
November 2020

Long-term Follow-up of Psilocybin-facilitated Smoking Cessation

Matthew W. Johnson, PhD, Albert Garcia-Romeu, PhD, and Roland R. Griffiths, PhD
July 2016

A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder

Feder A, Costi S, Rutter SB, Collins AB, Govindarajulu U, Jha MK, Horn SR, Kautz M, Corniquel M, Collins KA, Bevilacqua L, Glasgow AM, Brallier J, Pietrzak RH, Murrough JW, Charney DS
February 2021

A Single Dose of 5-MeO-DMT Stimulates Cell Proliferation, Neuronal Survivability, Morphological and Functional Changes in Adult Mice Ventral Dentate Gyrus

Rafael Vitor Lima da Cruz, Thiago C. Moulin, Lyvia Lintzmaier Petiz, and Richardson N. Leão
September 2018

Details